Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (191-200 of 250) with videos related to

Pageof 25
Sort By:
Annals of Clinical and Translational Neurology|November 18, 2021
Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter studyFriedemann Paul, Peter A Calabresi, Frederik Barkhof, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 24, 2009
Tear analysis in clinically isolated syndrome as new multiple sclerosis criterionGauthier Calais, Gerard Forzy, Charlotte Crinquette, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 16, 2013
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialPatrick Vermersch, Anna Czlonkowska, Luigi M E Grimaldi, et al.
JAMA Network Open|September 28, 2022
Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical TrialPatrick Vermersch, Matthew Scaramozza, Seth Levin, et al.
Multiple Sclerosis and Related Disorders|May 27, 2015
Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering GroupPeter Rieckmann, Alexey Boyko, Diego Centonze, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosisGiancarlo Comi, Yuval Dadon, Nissim Sasson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 9, 2022
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trialDouglas L Arnold, Daniela Piani-Meier, Amit Bar-Or, et al.
Neurology and Therapy|July 14, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis TreatmentStephen L Hauser, Ludwig Kappos, Amit Bar-Or, et al.
Neurodegenerative Disease Management|April 7, 2026
A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS studyKlaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Neurology and Therapy|July 4, 2025
Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS StudyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Pageof 25

Showing results (191-200 of 250) with videos related to

Sort By:
Pageof 25
Annals of Clinical and Translational Neurology|November 18, 2021
Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter studyFriedemann Paul, Peter A Calabresi, Frederik Barkhof, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 24, 2009
Tear analysis in clinically isolated syndrome as new multiple sclerosis criterionGauthier Calais, Gerard Forzy, Charlotte Crinquette, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 16, 2013
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialPatrick Vermersch, Anna Czlonkowska, Luigi M E Grimaldi, et al.
JAMA Network Open|September 28, 2022
Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical TrialPatrick Vermersch, Matthew Scaramozza, Seth Levin, et al.
Multiple Sclerosis and Related Disorders|May 27, 2015
Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering GroupPeter Rieckmann, Alexey Boyko, Diego Centonze, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosisGiancarlo Comi, Yuval Dadon, Nissim Sasson, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 9, 2022
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trialDouglas L Arnold, Daniela Piani-Meier, Amit Bar-Or, et al.
Neurology and Therapy|July 14, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis TreatmentStephen L Hauser, Ludwig Kappos, Amit Bar-Or, et al.
Neurodegenerative Disease Management|April 7, 2026
A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS studyKlaus Schmierer, Heinz Wiendl, Frederik Barkhof, et al.
Neurology and Therapy|July 4, 2025
Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS StudyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Pageof 25